Search results
Results from the WOW.Com Content Network
5327 18791 Ensembl ENSG00000104368 ENSMUSG00000031538 UniProt P00750 P11214 RefSeq (mRNA) NM_033011 NM_000930 NM_000931 NM_001319189 NM_008872 RefSeq (protein) NP_000921 NP_001306118 NP_127509 NP_032898 Location (UCSC) Chr 8: 42.17 – 42.21 Mb Chr 8: 23.25 – 23.27 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Tissue-type plasminogen activator, short name tPA, is a protein that ...
Plasminogen activator inhibitor-1 is a serine protease, synthesized by endothelial cells, that specifically inhibits tissue plasminogen activator (tPA) and urokinase (uPA). Tissue plasminogen activator and urokinase are the activators of plasminogen and result in the breakdown of blood clots (fibrinolysis). [4]
Reteplase, trade names include Retavase, is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.. Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein.
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter. [5]
Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition. Plasmin is a serine protease that acts to dissolve fibrin blood clots. Apart from fibrinolysis, plasmin proteolyses proteins in various other systems: It activates collagenases, some mediators of the complement system, and weakens the wall of the Graafian follicle, leading to ovulation.
Fibrinolysis is a process that prevents blood clots from growing and becoming problematic. [1] Primary fibrinolysis is a normal body process, while secondary fibrinolysis is the breakdown of clots due to a medicine, a medical disorder, or some other cause. [2] In fibrinolysis, a fibrin clot, the product of coagulation, is broken down. [3]
Activated platelets contract their internal actin and myosin fibrils in their cytoskeleton, which leads to shrinkage of the clot volume. Plasminogen activators, such as tissue plasminogen activator (t-PA), activate plasminogen into plasmin, which promotes lysis of the fibrin clot; this restores the flow of blood in the damaged/obstructed blood ...
Tissue plasminogen activator (TPA) is a serine protease occurring in animals including humans. Human-identical TPA (produced industrially by genetically recombinant microorganisms) has an established medical use in the treatment of ischemic stroke: by its proteolytic activity it enables the action of another enzyme (plasmin), which breaks down the protein (fibrin) of blood clots.